Merck KGAA

All figures EUR million unless stated; source: AR 2025 "Business Development 2021–2025" (which may include historically adjusted values), AR 2025 reconciliation tables, and FY2023/FY2024 annual reports. IFRS basis unless marked non-IFRS.

Income statement

Notes: Gross profit FY2021–FY2023 was not captured from primary sources during preparation and is shown as "not captured" rather than estimated. EPS pre FY2022: company reported EUR 10.06 (recalled from FY2022 release); one aggregator shows EUR 10.05 — discrepancy noted. EPS pre FY2023 EUR 8.49 confirmed in AR 2024. Merck KGaA reports no dilutive instruments, so basic and diluted EPS are identical. FY2025 dividend of EUR 2.20 approved by the AGM on 24 April 2026 (15th consecutive year of stable or rising dividend).

Margins and growth

Derived from 6.1 except organic growth (company), FY2024/FY2025 R&D ratio (company: 10.8% / 11.4%). EBITDA pre CAGR FY2021–FY2025: 0.0%. Over Garijo's 2021–2025 tenure the company states sales rose 20%, EBITDA pre 17%, OCF 13%, EPS 31% and DPS 57% (CEO letter AR 2025; base year appears to be FY2020).

Commentary. The five-year picture is one of a Covid-inflated peak in FY2022 followed by a plateau. Net sales of ~EUR 21bn have been flat for three years because organic growth (FY2024 +2.0%, FY2025 +3.1%) was consumed by currency headwinds (FY2025 FX -3.7% on sales, -5.0% on EBITDA pre). The EBITDA pre margin troughed at 28.0% in FY2023 (Life Science destocking and semiconductor downturn) and has recovered modestly to 28.9%, helped by Healthcare's mix (Mavenclad, CM&E) and efficiency programmes. IFRS profitability has deteriorated more than "pre" metrics: EBIT margin fell from 21.2% to 17.1% and profit after tax from EUR 3,339m to EUR 2,615m, reflecting higher amortisation of acquired intangibles (EUR 771m in FY2025), higher net financing costs after the SpringWorks financing (net financial result EUR -293m vs EUR -108m), and integration/restructuring charges. The gap between EPS (6.00) and EPS pre (8.34) widened to EUR 2.34 in FY2025, a quality-of-earnings point investors should monitor as Bio-Techne adds further amortisation.

Balance sheet

Source: AR 2025 five-year overview; total liabilities from AR 2025 consolidated balance sheet / Capital IQ via fintel (total assets − equity). Net financial debt at 30 June 2026: EUR 9,207m (Q2 2026). Working capital: the company's "net working capital" KPI (inventories + trade receivables − trade payables) was not captured; current liabilities were not captured, so a current ratio cannot be computed reliably and is flagged "not captured." Pension provisions (material for a German group and relevant to EV calculations) were not captured.

Commentary. The balance sheet is conservatively financed: equity ratio peaked at 58.1% (FY2024), and net financial debt fell from EUR 8.75bn (post-Versum) to EUR 7.16bn before re-levering to EUR 8.62bn after SpringWorks (FY2025) and EUR 9.21bn by mid-2026 (dividend timing and variable compensation). Equity declined EUR 1.3bn in FY2025 despite EUR 2.6bn of profit, consistent with large negative currency translation effects (USD weakness) on US-dollar-denominated goodwill — goodwill fell EUR 1.17bn even though SpringWorks was added. The debt maturity structure was extended in 2025 (non-current share rose to 90%) through the US$4bn senior bond (August 2025) and a EUR 850m hybrid (November 2025). Goodwill and intangibles of EUR 25.6bn equal 89% of equity — high but typical of an acquisitive tools/pharma group; impairment risk is concentrated in Life Science (Sigma-Aldrich/Millipore goodwill) and, prospectively, Bio-Techne.

Cash flow

Sources: AR 2025 five-year overview and free cash flow table. Company-defined FCF (new KPI from FY2026) = OCF − adjusted investment payments + adjusted disposal proceeds − lease payments, excluding collaboration/licensing payments and the PRV sale (AR 2025). Dividends paid: shareholder dividends on the 129.2m free-float shares equal ~EUR 284m per year at EUR 2.20 (AGM 2026 convening notice states EUR 284,332,954.40 total distribution to shareholders for FY2025); the corresponding profit withdrawal by E. Merck KG on its 70.274% general-partner capital is reported separately and was not captured. Merck KGaA does not conduct share buybacks; no authorisation is in place (KGaA structure).

Commentary. Cash generation weakened in FY2025: OCF fell 14.3% to EUR 3.93bn on working-capital build (EUR -349m, mainly inventories and receivables), higher interest (EUR -293m) and other liabilities movements, while FY2024 benefited from working-capital release. The investment cycle peaked in FY2023–FY2024 (PP&E capex ~8–9% of sales under the "region-for-region" programme: >EUR 7bn invested in >30 sites since 2021, per CEO letter). Management expects the capex-to-sales ratio to normalise gradually. FY2026 guidance: FCF EUR 1.8–2.3bn (upgraded August 2026 from EUR 1.5–2.0bn). H1 2026 OCF rose 26.7% to EUR 1,423m.

Ratios

All ratios derived by the analyst from AR 2025 five-year data. ROIC uses a 22% notional tax rate (the company's stated underlying tax rate for EPS pre) and year-end invested capital; it is an approximation and differs from the company's ROCE KPI (EBIT pre / operating assets), which is not published in the materials reviewed. Net financial result derived as EBIT minus PBT. Current ratio and cash conversion cycle: not computable from captured data (current liabilities and trade payables not captured); flagged "not captured." Payout ratio vs. the company's 20–25% target corridor: FY2025 slightly above the corridor, reflecting the policy that the current dividend is a floor.

Commentary. Return metrics have declined steadily since FY2021 because the capital base expanded (PP&E +38%, acquisitions) while earnings normalised after the Covid peak. ROE below 10% and approximate ROIC of ~7.5% are modest relative to the company's WACC (not disclosed; likely ~7–8%), which underlines why the capex normalisation and FCF focus announced for 2026 matter. Leverage remains well inside the company's informal comfort zone (well below 1.5x per CEO letter, though the letter also cites "below two" for FY2025); the Bio-Techne transaction (EV EUR 9.9bn against Bio-Techne EBITDA of ~US$0.2–0.4bn) will lift net debt/EBITDA pre materially — analyst estimate ~2.6–2.8x at closing, before deleveraging (estimate, not company guidance).

Quarterly trajectory

Sources: Q1 2026 Financial Statement (quarterly history), Q2 2026 press release, 2025 quarterly presentations. Q3 2025 EBITDA pre was supported by the PRV sale and one-time items. Q4 2025 IFRS EPS of EUR 0.73 reflects significant adjustments/impairments in the quarter (detail not captured). Q2 2026 IFRS EPS fell 24.7% while EPS pre rose 6.9%, indicating elevated adjustments (Bio-Techne transaction costs, restructuring) — composition not captured.

Management guidance for FY2026 (as upgraded 6 August 2026)

Source: Q2 2026 press release. Assumptions: no US Mavenclad sales from August 2026; excludes potential US Pergoveris commercialisation; excludes Bio-Techne. Guidance evolution in 2026: March (sales EUR 20.0–21.1bn, EBITDA pre EUR 5.5–6.0bn, EPS pre EUR 7.10–8.00) → May (EBITDA pre EUR 5.7–6.1bn) → August (as above).

Consensus growth expectations

Data-provider consensus (ftd.de, September 2026): EPS (pre basis) EUR 8.42 for 2026 and EUR 8.91 for 2027, implying ~6% growth in 2027. Medium-term company target: mid-single-digit organic sales growth.

Bull case

1. Three engines firing simultaneously: Process Solutions (+14.7% organic Q2 2026), Semiconductor Solutions (+17.3%) and Rare Diseases (EUR 207m H1 2026 sales) are all accelerating, and management expects them to drive up to 80% of medium-term growth; Electronics EBITDA pre is guided up 25–29% organically in 2026.

2. Bio-Techne transforms Life Science quality: it adds high-margin proteins/antibodies, spatial biology and analytical instruments, closes Merck's portfolio gap versus Thermo Fisher/Danaher, and carries EUR 140m of identified cost synergies; regulatory hurdles are being cleared on schedule (HSR, German FCO, shareholder vote).

3. Valuation leaves room: at ~16x 2026 EPS pre and ~11x EV/EBITDA pre, the group trades at a large discount to pure-play peers; Healthcare's Mavenclad cliff is now largely in guidance, so 2027 should show cleaner growth and margin expansion, plus FCF upside as capex normalises.

Bear case

1. Healthcare is shrinking organically: guided -4% to -2% organic sales and -8% to -5% organic EBITDA pre for 2026, with Mavenclad (EUR 1.2bn), Rebif and Bavencio all declining and a pipeline that has disappointed repeatedly; Rare Diseases (~EUR 0.4–0.5bn annualised) cannot yet offset the losses.

2. Bio-Techne is expensive and levering: EV of US$11.3bn against Bio-Techne revenue of ~US$1.2bn (~9x sales) and reported EBITDA of ~US$213m; EPS pre accretion only by year 3; net debt likely to rise toward ~EUR 19bn on closing (analyst estimate), constraining further M&A and inviting rating pressure.

3. Earnings quality and returns erosion: IFRS EPS has fallen four years running (EUR 7.65 → 6.00), ROE has dropped to ~9%, and the widening gap between IFRS and "pre" earnings will grow with Bio-Techne amortisation; FX remains a recurring drag.

Key catalysts and monitorables (next 12 months)

Concluding analyst verdict

Merck KGaA enters the Beckmann era as a fundamentally sound but under-earning conglomerate whose investment case is shifting decisively toward Life Science and semiconductors. The evidence of 2025–2026 is encouraging at the operating level: organic growth has improved each half (FY2025 +3.1%; Q2 2026 +4.1%), EBITDA pre margins are holding near 29% despite heavy currency headwinds, and FY2026 guidance has been raised twice. Process Solutions and Semiconductor Solutions are in clear cyclical and structural upswings, the former driven by biologics and novel modalities, the latter by AI-related advanced-node and packaging demand.

The offsetting weakness is Healthcare, which is now in managed decline organically as Mavenclad loses US exclusivity and older oncology and MS brands erode. The SpringWorks assets are performing in line with plans, but the franchise is too small to compensate before 2027–2028, and the internal pipeline has not yet earned investor trust. Reported (IFRS) earnings and returns on capital have trended down for four years, a reminder that "pre" metrics flatter the picture.

The Bio-Techne acquisition is the defining strategic bet. It is logical — it fills gaps in proteins, spatial biology and analytics and deepens workflow integration — but it is priced richly and pushes leverage up at a time when Healthcare cash flows are under pressure. Execution, synergy delivery and disciplined deleveraging will determine whether the deal closes the valuation gap to tools peers or entrenches the conglomerate discount.

On balance, at roughly 16x forward EPS pre and ~11x EV/EBITDA pre, the shares discount much of the Healthcare erosion while ascribing limited value to the Life Science and Electronics upturns. The analyst stance is constructive but conditional: positive risk-reward over 12–24 months, contingent on clean Bio-Techne closing and financing, visible Rare Diseases scaling, and 2027 guidance that demonstrates group-level organic growth in the mid-single digits with stable-to-rising margins. Key downside triggers would be a Life Science demand air-pocket after the 2026 Asian stocking, rating pressure, or further pipeline failures.